What is Wedbush’s Estimate for Arvinas Q1 Earnings?

Arvinas, Inc. (NASDAQ:ARVN) – Stock analysts at Wedbush issued their Q1 2026 earnings per share estimates for Arvinas in a research report issued to clients and investors on Wednesday, November 5th. Wedbush analyst R. Driscoll anticipates that the company will post earnings per share of ($0.63) for the quarter. Wedbush currently has a “Neutral” rating and a $9.00 price target on the stock. The consensus estimate for Arvinas’ current full-year earnings is ($3.81) per share. Wedbush also issued estimates for Arvinas’ Q2 2026 earnings at ($0.65) EPS.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.27. The business had revenue of $41.90 million during the quarter, compared to the consensus estimate of $29.36 million. Arvinas had a negative return on equity of 9.58% and a negative net margin of 18.73%.The firm’s revenue for the quarter was down 59.1% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.68) EPS.

Several other analysts have also recently commented on ARVN. Bank of America cut shares of Arvinas from a “buy” rating to a “neutral” rating and set a $10.00 price target on the stock. in a research note on Wednesday, September 24th. Stephens dropped their price target on Arvinas from $16.00 to $14.00 and set an “overweight” rating for the company in a research note on Thursday, September 18th. HC Wainwright reduced their price objective on Arvinas from $24.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, August 7th. Guggenheim lowered their target price on Arvinas from $16.00 to $15.00 and set a “buy” rating for the company in a research report on Thursday, August 7th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Arvinas in a report on Wednesday, October 8th. Eleven research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Arvinas presently has an average rating of “Hold” and a consensus price target of $16.34.

Arvinas Trading Down 1.3%

Shares of NASDAQ:ARVN traded down $0.13 during midday trading on Friday, reaching $9.87. 220,376 shares of the company were exchanged, compared to its average volume of 2,164,310. The stock has a market cap of $724.58 million, a PE ratio of -12.19 and a beta of 2.38. The business’s fifty day moving average is $8.77 and its two-hundred day moving average is $7.90. Arvinas has a one year low of $5.90 and a one year high of $28.70.

Institutional Investors Weigh In On Arvinas

Several hedge funds and other institutional investors have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd lifted its position in shares of Arvinas by 965.4% during the first quarter. Caitong International Asset Management Co. Ltd now owns 4,656 shares of the company’s stock worth $33,000 after purchasing an additional 4,219 shares during the last quarter. Tower Research Capital LLC TRC raised its position in shares of Arvinas by 491.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,819 shares of the company’s stock worth $43,000 after acquiring an additional 4,835 shares in the last quarter. Canada Pension Plan Investment Board lifted its position in shares of Arvinas by 109.4% during the second quarter. Canada Pension Plan Investment Board now owns 6,700 shares of the company’s stock valued at $49,000 after buying an additional 3,500 shares during the last quarter. CWM LLC grew its holdings in Arvinas by 2,317.5% in the first quarter. CWM LLC now owns 7,615 shares of the company’s stock worth $53,000 after purchasing an additional 7,300 shares during the last quarter. Finally, State of Wyoming purchased a new stake in shares of Arvinas during the 3rd quarter valued at $68,000. 95.19% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Briggs Morrison acquired 30,000 shares of the firm’s stock in a transaction on Monday, September 22nd. The stock was acquired at an average price of $7.57 per share, with a total value of $227,100.00. Following the completion of the purchase, the director directly owned 76,021 shares in the company, valued at approximately $575,478.97. This trade represents a 65.19% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 4.73% of the company’s stock.

Arvinas declared that its Board of Directors has initiated a stock buyback plan on Wednesday, September 17th that allows the company to buyback $100.00 million in outstanding shares. This buyback authorization allows the company to purchase up to 17.9% of its shares through open market purchases. Shares buyback plans are often a sign that the company’s board of directors believes its stock is undervalued.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.